Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms.
- Author:
Kirill Vladimirovich KOSILOV
1
;
Loparev Sergay ALEXANDROVICH
;
Kuzina Irina GENNADYEVNA
;
Shakirova Olga VIKTOROVNA
;
Zhuravskaya Natalia SERGEEVNA
;
Ankudinov Ivan IVANOVICH
Author Information
- Publication Type:Original Article
- Keywords: Urinary Bladder, Overactive; Muscarinic Antagonists; Solifenacin Succinate; Compliance
- MeSH: Caffeine; Cohort Studies; Compliance*; Diagnosis; Education; Employment; Health Expenditures; Humans; Lower Urinary Tract Symptoms*; Muscarinic Antagonists; Prevalence; Salaries and Fringe Benefits; Solifenacin Succinate*; Transportation; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination Disorders
- From:International Neurourology Journal 2016;20(3):240-249
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The prevalence of hyperactive-type lower urinary tract symptoms is 45.2%, with shares of overactive bladder (OAB) and urge incontinence (UI) symptoms of 10.7% and 8.2%, respectively. We investigated the possible impact of a wide range of social, economic, and medical factors on compliance with solifenacin treatment in the working population. METHODS: Social, economic, and medical factors as well as the Overactive Bladder questionnaire – the OAB-q Short Form (OAB-q SF), bladder diaries, and uroflowmetry of 1,038 people who were administered solifenacin for a year were gathered from employer documentation. RESULTS: Among the subjects, 32% maintained their compliance with solifenacin treatment throughout the year. Only 65% of the patients had compliance exceeding 80%, and 17% of patients had compliance of ≥50%, yet less than 80% were still taking solifenacin 12 months after the beginning of this experiment. Working people whose compliance level was, at least, 80% had reliably higher (P≤0.01) average age, annual salary, and treatment efficacy, and a greater treatment satisfaction level, as well as a lack of satisfaction with other antimuscarinic treatments and higher rate of urge UI diagnosis. The same cohort also featured a lower level (P≤0.01) of caffeine abuse and lower share of salary spent purchasing solifenacin. CONCLUSIONS: This study has shown that compliance with solifenacin treatment is associated with a number of significant medical, social, and economic factors. The medical factors included the type of urination disorder, severity of incontinence symptoms, presence of side effects, treatment efficacy and patients’ satisfaction with it, and experience using other antimuscarinic treatments. Among the social and economic factors, those with the strongest correlation to compliance were patient age, employment in medicine and education, annual income level, percentage of solifenacin purchase expenditures, and caffeine abuse. Factors with a weaker, but still significant, association were gender, employment in the transportation industry, and monthly income level.
